{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-017354","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.310510+00:00","generated_at":"2026-06-03T02:36:25.165449+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cocrystal Pharma completes enrollment of 78 subjects in Phase 2a study of CC-42344 for influenza A","bullets":["Enrolled 78 healthy subjects in randomized, double-blind, placebo-controlled Phase 2a human challenge study of oral PB2 inhibitor CC-42344.","Study evaluating safety, tolerability, antiviral and clinical measurements of CC-42344 for pandemic and seasonal influenza A.","Topline results expected later this year; study conducted in the United Kingdom.","Company also plans to begin Phase 1 study in Australia with inhaled formulation of CC-42344.","Received positive Pre-IND feedback from FDA in March 2024 guiding Phase 2b protocol."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-017354","json":"https://secwatch.observer/filing/0001493152-24-017354.json","markdown":"https://secwatch.observer/filing/0001493152-24-017354.md","text":"https://secwatch.observer/filing/0001493152-24-017354.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224017354/0001493152-24-017354-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224017354/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:36:25.165449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}